These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 11365212)

  • 21. Improved but not new.
    Vazquez E
    Posit Aware; 1997; 8(6):19. PubMed ID: 11364855
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Finding a role for zalcitabine in the HAART era.
    Moyle GJ; Gazzard BG
    Antivir Ther; 1998; 3(3):125-37. PubMed ID: 10682130
    [TBL] [Abstract][Full Text] [Related]  

  • 23. AVANTI 3: a randomized, double-blind trial to compare the efficacy and safety of lamivudine plus zidovudine versus lamivudine plus zidovudine plus nelfinavir in HIV-1-infected antiretroviral-naive patients.
    Gartland M;
    Antivir Ther; 2001 Jun; 6(2):127-34. PubMed ID: 11491417
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Update from the 5th Conference on Retroviruses and Opportunistic Infections.
    Vazquez E
    Posit Aware; 1998; 9(3):21-3. PubMed ID: 11365483
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Saquinavir/Ritonavir: its evolution and current treatment role.
    O'Brien WA
    AIDS Read; 2006 Jan; 16(1):38-44; discussion 43. PubMed ID: 16433471
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The history of antiretrovirals: key discoveries over the past 25 years.
    De Clercq E
    Rev Med Virol; 2009 Sep; 19(5):287-99. PubMed ID: 19714702
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Contraindicated antiretroviral drug combinations.
    Macher A; Thomas D; Paul SM
    N J Med; 2003 Sep; 100(9 Suppl):41-3; quiz 73-4. PubMed ID: 14556602
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A prospective study of efficacy and safety of once-daily saquinavir/ritonavir plus two nucleoside reverse transcriptase inhibitors in treatment-naive Thai patients.
    Ananworanich J; Hill A; Siangphoe U; Ruxrungtham K; Prasithsirikul W; Chetchotisakd P; Kiertiburanakul S; Munsakul W; Raksakulkarn P; Tansuphasawadikul S; Nuesch R; Cooper DA; Hirschel B;
    Antivir Ther; 2005; 10(6):761-7. PubMed ID: 16218176
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antiretroviral effect of two different dose regimens of ritonavir and saquinavir on HIV-infected adults in a population-based setting.
    Jahnke N; Seminari E; Hogg RS; Yip B; O'Shaughnessy MV; Montaner JS
    Antivir Ther; 1999; 4(3):151-6. PubMed ID: 12731754
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A randomized, open-label, comparative trial of BID and TID dosing of saquinavir enhanced oral formulation as part of a triple therapy for advanced AIDS patients.
    Chetchotisakd P; Anunnatsiri S; Wankun J; Mootsikapun P; Boonyaprawit P
    J Med Assoc Thai; 2002 May; 85(5):590-6. PubMed ID: 12188390
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The 48-week efficacy of once-daily saquinavir/ritonavir in patients with undetectable viral load after 3 years of antiretroviral therapy.
    Cardiello P; Srasuebkul P; Hassink E; Mahanontharit A; Samor T; Ruxrungtham K; Lange J; Cooper D; Phanuphak P
    HIV Med; 2005 Mar; 6(2):122-8. PubMed ID: 15807718
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Improving the pharmacokinetics of protease inhibitors in a more innovative manner. HIV drugs administered in a more clever way].
    MMW Fortschr Med; 2001 Apr; 143 Suppl 1():18-21. PubMed ID: 11373769
    [No Abstract]   [Full Text] [Related]  

  • 33. Pregnancy danger.
    Posit Aware; 1998; 9(5):18. PubMed ID: 11365886
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antiviral therapy: how simple can you get?
    Gilden D
    GMHC Treat Issues; 1998 Nov; 12(11):3-7. PubMed ID: 11365906
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Any toxic relief in sight? The induction/maintenance approach to therapy.
    Gomez E
    Newsline People AIDS Coalit N Y; 1998 Sep; ():33. PubMed ID: 11367488
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of lopinavir/ritonavir monotherapy on quality of life and self-reported symptoms among antiretroviral-naive patients: results of the MONARK trial.
    Spire B; Marcellin F; Cohen-Codar I; Flandre P; Boue F; Dellamonica P; Raffi F; Norton M; Van Philippe N; Delfraissy JF
    Antivir Ther; 2008; 13(4):591-9. PubMed ID: 18672538
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antiretroviral efficacy and virological profile of a zidovudine/lamivudine/tenofovir disoproxil fumarate combination therapy in antiretroviral-naive patients.
    Masquelier B; Neau D; Boucher S; Lavignolle-Aurillac V; Schrive MH; Recordon-Pinson P; Ragnaud JM; Fleury H
    Antivir Ther; 2006; 11(6):827-30. PubMed ID: 17310827
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anti-HIV drugs.
    De Clercq E
    Verh K Acad Geneeskd Belg; 2007; 69(2):81-104. PubMed ID: 17550060
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Understanding the reverse transcriptase inhibitors in HIV.
    Edmonds-Ogbuokiri J
    Fac Notes (New Orleans La); 1998; 10(6):13-5. PubMed ID: 11366142
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lamivudine and indinavir/ritonavir maintenance therapy in highly pretreated HIV-infected patients (Vista ANRS 109).
    Launay O; Duval X; Dalban C; Descamps D; Peytavin G; Certain A; Mouajjah S; Ralaimazava P; Verdon R; Costagliola D; Clavel F;
    Antivir Ther; 2006; 11(7):889-99. PubMed ID: 17302251
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.